Please login to the form below
ozanimod
This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
The news is very welcome for Celgene, which has suffered numerous setbacks in recent months, including the FDA refusing to accept the filing of ozanimod in February.
Latest news
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Smith looked to have paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
This looks like Smith has paid the price for some costly slip-ups in recent months, most notably the FDA’s refused to review Celgene’s multiple sclerosis drug, ozanimod.
-
Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more
new drugs, multiple sclerosis candidate ozanimod - and all because the company had failed to provide adequate non-clinical and clinical pharmacology data in its dossier.
-
FDA turns down Celgene’s filing for multiple sclerosis drug
Celgene is facing a delay for its multiple sclerosis candidate ozanimod in the US and elsewhere as the FDA has refused to accept its marketing application for the drug. ... The embarrassing setback has arisen because of deficiencies in the “nonclinical
-
Sanofi licences Principia MS drug in $805m deal
And an even bigger threat is looming in the shape of Celgene’s ozanimod, a once-daily oral therapy that GBI Research has predicted could make rapid headway thanks to a
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Pharma deals in July 2015
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Manager
-
Negotiable
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Associate Scientific Director
-
Salary TBC
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Sudler London - Account Director
-
Competitive
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
-
Healthcare PR Senior Account Manager
-
Salary TBC
-
Systematic Review Lead- London
-
Negotiable
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
